<span item_type="fundamental" item_id="a11c7645a7f44fcca084732a83094f8e" counter_id="ST/US/BTAI" env="prod"></span><span item_type="announcement" item_id="648600704003016065" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 206 K, missing the estimate of USD 381.49 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.54.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -6.236 M.</p><p></p><h4>Product Revenues</h4><p>BioXcel Therapeutics, Inc. reported product revenues of $206 thousand for the first quarter of 2026, an increase from $168 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Cost of Goods Sold</h4><p>Cost of Goods Sold for the first quarter of 2026 was $283 thousand, compared to $14 thousand for the first quarter of 2025, primarily due to higher charges for reserves for excess or obsolete inventory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Research and Development (R&amp;D) Expenses</h4><p>Research and Development expenses decreased to $2,955 thousand for the first quarter of 2026 from $4,554 thousand in the same period of 2025, mainly due to the completion of the SERENITY At-Home pivotal Phase 3 safety trial in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Selling, General and Administrative (SG&amp;A) Expenses</h4><p>Selling, General and Administrative expenses increased to $7,191 thousand for the first quarter of 2026, up from $5,699 thousand in the first quarter of 2025, primarily driven by an increase in professional fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Total Operating Expenses</h4><p>Total operating expenses were $10,429 thousand for the first quarter of 2026, compared to $10,267 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Loss from Operations</h4><p>BioXcel Therapeutics, Inc. reported an operating loss of - $10,223 thousand for the first quarter of 2026, slightly higher than the operating loss of - $10,099 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Interest Expense, net</h4><p>Net interest expense was $4,198 thousand for the first quarter of 2026, compared to $3,993 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Interest Income</h4><p>Interest income was - $211 thousand for the first quarter of 2026, compared to - $279 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Other (income) expense, net</h4><p>Other (income) expense, net was - $1,519 thousand for the first quarter of 2026, compared to - $6,559 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Net Loss</h4><p>BioXcel Therapeutics, Inc. reported a net loss of - $12,691 thousand for the first quarter of 2026, an increase from a net loss of - $7,254 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Net Loss Per Share</h4><p>Net loss per share - basic and diluted was - $0.54 for the first quarter of 2026, compared to - $1.50 for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Weighted Average Shares Outstanding</h4><p>Weighted average shares outstanding - basic and diluted were 23,571 thousand for the first quarter of 2026, compared to 4,834 thousand for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Cash and Cash Equivalents and Restricted Cash</h4><p>Cash and cash equivalents and restricted cash totaled $17,180 thousand as of March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Total Assets</h4><p>Total assets were $34,025 thousand as of March 31, 2026, down from $44,916 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Total Liabilities</h4><p>Total liabilities were $139,568 thousand as of March 31, 2026, a slight decrease from $140,379 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Total Stockholders’ Equity (Deficit)</h4><p>Total stockholders’ equity (deficit) was - $105,543 thousand as of March 31, 2026, compared to - $95,463 thousand as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p><h4>Outlook / Guidance</h4><p>BioXcel Therapeutics, Inc. announced that the FDA accepted its supplemental New Drug Application (sNDA) for IGALMI® for at-home use, with a PDUFA target action date of November 14, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span> The company is exploring strategic options for the IGALMI franchise and preparing for its commercial launch in the at-home setting.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span> Additionally, BioXcel Therapeutics, Inc. continues to focus on the potential of BXCL501 in Alzheimer’s dementia.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_ex99-1.htm"></span></p>

Bioxcel Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 206 K